二至丸合桂枝汤治疗三阴性乳腺癌的临床研究

Clinical Study of Erzhi Pill and Guizhi Decoction on the Treatment of Triple Negative Breast Cancer

关键词:  三阴性乳腺癌  二至丸  桂枝汤  生活质量

Key words:  triple negative breast cancer  erzhi pill  guizhi decoction  quality of life

摘要:

目的 观察二至丸合桂枝汤治疗三阴性乳腺癌(triple negative breast cancer，TNBC)的临床疗效。方法 回顾性分析乳腺科2013年1月—2015年1月期间确诊的100例TNBC病例资料，以术后行常规辅助化疗的病例资料为对照组(50例)，加用二至丸合桂枝汤治疗的病例资料为治疗组(50例)。进行为期5年的随访，对比分析2组间疗效、身体机能、生活质量、肿瘤标志物水平的差异，记录治疗期间不良事件发生情况，同时比较5年总生存率、无病生存率及复发转移率的差化。结果 治疗组总有效率为80.00%，高于对照组62.00%(P<0.05)。治疗后，治疗组KPS评分提高稳定率82.00%高于对照组70.00%(P<0.05)，FACT-B评分高于对照组(P<0.05)。治疗组血清肿瘤标志物CEA、CA125及CA153水平降低且低于对照组(P<0.05)。治疗组胃肠道不良反应发生程度较对照组轻(P<0.05)。治疗组5年总生存率和无病生存率分别为88.00%和62.00%，高于对照组的72.00%和42.00%(P<0.05)。结论 二至丸合桂枝汤辅助化疗对TNBC患者作用效果显著，可提高患者生活质量，远期疗效佳，值得临床应用。

Abstract:

b>OBJECTIVE To study the clinical efficacy of Erzhi pill and Guizhi decoction in the treatment of triple negative breast cancer(TNBC). METHODS The data of 100 TNBC cases diagnosed in breast department from January 2013 to January 2015 were retrospectively analyzed. The case data of routine adjuvant chemotherapy after operation were the control group(50 cases), and the case data of the treatment group(50 cases) treated with Erzhi pill and Guizhi decoction. Five-year follow-up was conducted to compare and analyze the differences in efficacy, physical function, quality of life and tumor markers between the two groups. Adverse events during treatment were recorded, and differences in 5-year overall survival, disease-free survival, and recurrence and metastasis rates were compared. RESULTS The total effective rate of 80.00% in the treatment group was higher than that of 62.00% in the control group(P<0.05). After treatment, the stabilization rate of KPS score improvement in the treatment group was 82.00% which was higher than that in the control group of 70.00%(P<0.05), and the FACT-B score was higher(P<0.05). The levels of serum tumor markers CEA, CA125 and CA153 in the treatment group were decreased and lower than control troup(P<0.05). The gastrointestinal adverse reactions in the treatment group were milder than control troup(P<0.05). The 5-year overall survival rate and disease-free survival rate of 88.00% and 62.00% in the treatment group which was were higher than those of 72.00% and 42.00% in the control group (P<0.05). CONCLUSION Erzhi pill and Guizhi decoction have significant effect on TNBC patients, which can improve the life quality of patients, and have good long-term effect, which is worthy of clinical application.